Wall Street Zen Upgrades Recursion Pharmaceuticals (NASDAQ:RXRX) to "Hold"

Key Points

• Wall Street Zen upgraded Recursion Pharmaceuticals (NASDAQ: RXRX) from “sell” to “hold.” Overall analyst consensus is also “hold,” with a consensus price target of $8.18.
• The company reported quarterly EPS of -$0.22, matching estimates, while revenue of $18.55 million exceeded the $14.81 million consensus.
• Company insiders sold 167,408 shares worth about $701,000 over the past three months; the reported sales were made under pre-arranged trading plans.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

RXRX has been the subject of a number of other research reports. Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a report on Friday, October 16th. Needham & Company LLC restated a "buy" rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $8.18.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX opened at $3.52 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. Recursion Pharmaceuticals has a one year low of $2.77 and a one year high of $5.24. The firm has a market capitalization of $1.88 billion, a PE ratio of -3.91 and a beta of 1.15. The company has a 50-day simple moving average of $3.77 and a two-hundred day simple moving average of $3.52.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 46.47%. The firm had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. During the same period in the prior year, the firm posted ($0.36) earnings per share. On average, analysts anticipate that Recursion Pharmaceuticals will post -0.89 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the sale, the chief executive officer owned 2,072,890 shares of the company's stock, valued at $7,296,572.80. This represents a 1.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the company's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the sale, the director owned 162,156 shares of the company's stock, valued at $810,780. This trade represents a 13.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 167,408 shares of company stock valued at $701,276 over the last three months. 6.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. First Trust Advisors LP raised its holdings in shares of Recursion Pharmaceuticals by 15.2% during the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company's stock worth $8,015,000 after acquiring an additional 344,035 shares in the last quarter. Bank of America Corp DE increased its holdings in Recursion Pharmaceuticals by 18.2% during the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company's stock worth $7,665,000 after acquiring an additional 384,486 shares during the period. Renaissance Technologies LLC bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $7,370,000. Bank of New York Mellon Corp lifted its position in Recursion Pharmaceuticals by 29.3% during the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company's stock valued at $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its position in shares of Recursion Pharmaceuticals by 537.3% during the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company's stock worth $3,367,000 after purchasing an additional 689,903 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company's platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.